Revolutionizing Drug Delivery Through Oral Film Technology
At Nualtis, we leverage science and innovation to improve quality of life. We develop and manufacture innovative oral thin films to create novel and impactful treatments.
Our Oral Film Technology offers significant advantages
Our proprietary film technologies offer significant benefits over traditional dosage forms, creating better experiences for patients and improved treatment outcome.
Our oral films deliver medications directly through the mucosal lining. This results in faster onset of action, reduced dosage requirements, and minimized side effects compared to conventional tablets or capsules.
Intimate and prolonged contact with the oral mucosa allows for systemic absorption of the drug, thereby reducing first-pass metabolism and limiting stomach exposure. This opens up an oral path of administration for drugs that cannot be given as a tablet or capsule.
The innovative delivery method allows for precise control of drug release rates, enabling customized therapeutic profiles and reduced dosing frequency for improved patient convenience.
Nualtis films dissolve rapidly in the mouth without water, making medication administration easier. They are easy to carry, discreet, with a pleasant taste. Especially for pediatric patients, geriatric populations, animals, and those with swallowing difficulties the convenient format improves treatment adherence.
Our product platforms redefine patient outcomes
At Nualtis, we have been pioneering oral film technologies for over two decades. With unmatched depth in formulation expertise, Nualtis has emerged as a market leader in oral film development with over 30 patents just in the US.
Human Health
Our proprietary VersaFilm® platform forms the foundation of a growing portfolio of human health products.
Animal Health
Our VetaFilm (R) platform enables stress-free dosing for animals with palatable, room‑stable films that slip onto a pet's tongue, removing the fight from dosing and ensuring full therapeutic intake.
.avif)
Partnering
We partner with pharma leaders from concept to commercialization. We have an existing portfolio of products available for licensing deals.
Transform Your Drug Delivery Approach
Whether you're seeking to differentiate an existing product, want to develop a new product, or partner with us on our existing portfolio, our team can help enhance your therapeutic offerings through innovative film technology.
Our Services ensure seamless development and supply from start to finish
From concept to commercial supply, we provide the science, GMP capacity, and regulatory muscle to bring film‑based products to market worldwide.
R&D Partnerships
Our scientists co‑design prototypes with your team, run taste‑masking, PK, and stability studies, and hit milestones backed by data you can take straight to regulators.
GMP Manufacturing
Our plant is inspected by regulatory authorities and scales from pilot to millions of unit campaigns under strict cGMP, with full QA release, and serialization support.
Analytical & Regulatory
In‑house labs deliver method development, validation, and ICH stability, while our regulatory group authors master files and shepherd submissions through FDA, EMA, and global agencies.
Recent words from our trusted partners
Our partners value our scientific expertise, collaborative approach, and commitment to developing innovative solutions that address real-world therapeutic challenges.
Srinivas Rao, M.D.,Ph.D, atai CEO
Robert SpinaCEO, US Exeltis & Xiromed
Dr. Paul Zimmerman, Gensco Pharma CEO
Meet Our Expert Leadership Team
Our diverse team brings decades of collective experience in pharmaceutical sciences, drug delivery innovation, and successful commercialization.
Dr. Michael Raven, CEO
is the CEO of Nualtis, where he drives the company’s strategic direction and growth. He brings leadership experience from Bayer Pharmaceuticals, atai Life Sciences, and McKinsey & Company. With academic training in biotechnology, business, and innovation management, he is focused on advancing oral film drug delivery and building a high-performing team to improve therapeutic outcomes for humans and animals.
Nadine Paiement, CSO
is Chief Scientific Officer at Nualtis, overseeing oral film formulation and product development. With over 20 years in pharmaceutical R&D and degrees in Chemistry from the University of Sherbrooke, she leads the scientific advancement of Nualtis’ pipeline. Nadine specializes in transforming complex therapeutic needs into high-performance oral film drug delivery systems.
Nina Pourhassan, VP Quality
is VP of Quality Operations at Nualtis, with 20+ years of experience in QC, QA, and regulatory compliance. She holds a Ph.D. in Chemistry and has led successful FDA and Health Canada inspections. Nina focuses on building robust quality systems that support innovation and ensure compliance across human and animal health programs.
Karen Kalayajian, VP Finance & Admin
is VP of Finance at Nualtis, where she leads financial planning, controls, and strategic growth support. A CPA with 20+ years in pharma and biotech, she holds degrees in Accountancy from Concordia University. Karen brings strong financial leadership to support operational excellence and long-term expansion across human and veterinary health portfolios.
Tommy Kenny, BD Lead & General Counsel
is Business Development Lead and General Counsel at Nualtis. With legal and scientific training, he guides IP strategy, partnerships, and commercial development. Tommy holds law degrees and a Master’s in Chemistry, and brings over a decade of experience in pharma law. He aligns legal, business, and innovation strategy to drive company growth.
Let's Transform Your Drug Delivery
Connect with our team to explore how our innovative film technologies can enhance your therapeutic products, improve patient experiences, and create competitive advantages in the marketplace.